Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Objective</h3><p>To investigate ultrasound features of diaphragm motion and function in type 1 spinal muscular atrophy (SMA‐1) patients.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Design</h3><p>Prospective study.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Patients</h3><p>The study cohort included SMA‐1 children younger than 18‐year‐old. Control subjects included type 2 and type 3 SMA and other neuromuscular disorders younger than 18‐year‐old.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methodology</h3><p>Diaphragm ultrasound evaluating diaphragmatic excursion, speed of diaphragmatic contraction, duration of the respiratory cycle, inspiratory/expiratory relationship, end‐inspiratory and ‐expiratory thickness, thickening fraction, and pattern of contractility. The interrater reliability for each variable was established by calculation of Cohen's <i>k</i> coefficient. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>Twenty‐three SMA‐1 patients and 12 controls were evaluated. Diaphragm ultrasound values were within normal ranges in all study cohort patients and no difference was found with controls. There was a gradient of diaphragm function with SMA 1.9 subgroup having the best and SMA 1.1 having the worst parameters, particularly in end‐inspiratory thickness and diaphragmatic excursion (<i>P</i> = .031 and <i>P</i> = .041, respectively). Seventy‐four percent of SMA‐1 patients had a dysmotility pattern of diaphragm contraction, mostly represented in SMA 1.9 subgroup (<i>P</i> = .001). This pattern was observed in 92.8% of children on noninvasive ventilation (NIV) for less than 16 hours/d of and in 20% patients with invasive ventilation or NIV for more than 16 hours/d (<i>P</i> = .027). The dysmotility pattern was never observed in the control group. The levels of interobserver agreement were high for "diaphragm irregularities," "inspiratory/expiratory relationship," and "diaphragm thickness," and good for the other variables. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>Ultrasound can be used to evaluate diaphragm function and contractility in SMA‐1 children, providing additional information to the clinical examination and functional respiratory tests, describing a characteristic contractility pattern in these patients. Longitudinal studies are needed to understand the impact of diaphragm dysmotility and other parameters on long‐term outcome in SMA‐1 patients.</p></section>

Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study

Motor and neurocognitive profiles of children with symptomatic spinal muscular atrophy type 1 with two copies of SMN2 before and after treatment: a longitudinal observational study

Early spinal muscular atrophy treatment following newborn screening: A 20‐month review of the first Italian regional experience

Experience of a 2-year spinal muscular atrophy NBS pilot study in Italy: towards specific guidelines and standard operating procedures for the molecular diagnosis

Ultrasound assessment of diaphragmatic function in type 1 spinal muscular atrophy

Upper limb function changes over 12 months in untreated SMA II and III individuals: an item-level analysis using the Revised Upper Limb Module

Progress in treatment and newborn screening for Duchenne muscular dystrophy and spinal muscular atrophy

Identification of a cytokine profile in serum and cerebrospinal fluid of pediatric and adult spinal muscular atrophy patients and its modulation upon nusinersen treatment

Outcomes of early‐treated infants with spinal muscular atrophy: A multicenter, retrospective cohort study

An early Transcriptomic Investigation in Adult Patients with Spinal Muscular Atrophy Under Treatment with Nusinersen

Longitudinal changes of swallowing safety and efficiency in infants with spinal muscular atrophy who received disease modifying therapies

Quality of Life of Children with Spinal Muscular Atrophy and Their Caregivers from the Perspective of Caregivers: a Chinese Cross-Sectional Study

Impaired Neurodevelopment in Children with 5q-SMA - 2 Years After Newborn Screening

Pilot Study on Quantitative Cervical Cord and Muscular MRI in Spinal Muscular Atrophy: Promising Biomarkers of Disease Evolution and Treatment?

Pilot study of population-based newborn screening for spinal muscular atrophy in New York state

Long‐term natural history in type II and III spinal muscular atrophy: a 4‐year international study on the Hammersmith Functional Motor Scale Expanded

Parental diagnostic delay and developmental outcomes in congenital and childhood-onset myotonic dystrophy type 1

Clinical and molecular features and therapeutic perspectives of spinal muscular atrophy with respiratory distress type 1

Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study

Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls

Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial